HK Stock Market Move | CUTIA-B (02487) rises over 3%; CU-40102 recently received marketing approval from the Macao Pharmaceutical Administration Bureau.

CUTIA-B (02487) rose over 3%, up 3.77% as of press time, at HK$1.1, with a turnover of HK$147,400. On the news front, CUTIA-B announced that the group's CU-40102 (topical finasteride spray) has received marketing approval from the Pharmaceutical Administration Bureau of the Government of the Macao Special Administrative Region of China, with the approved indication being the treatment of androgenetic alopecia. This marks another major milestone for CU-40102 following its marketing approvals from China's National Medical Products Administration and the Department of Health of the Government of the Hong Kong Special Administrative Region of China. As an important product of the group to receive marketing approval in the field of hair diseases and care, CU-40102 is undergoing extensive commercialization in China. This approval will further deepen the international layout of CU-40102, broaden its market space, and benefit more patients with androgenetic alopecia.